Zhitong Financial App News, China Biopharmaceutical (01177.HK) issued an announcement. The final results of the Phase I clinical study of the national Class 1 innovative drug Kylo-11 “LPA siRNA” independently developed by Hangzhou Hejia Biomedical Co., Ltd. (“Hegia Biology”), a wholly-owned subsidiary of the Group, were released in the 2026 European Society of Cardiology Annual Meeting (ESC) in the form of an oral report; at the same time, the full study was published in the top international medical journal “Liu “Leaf Knives” (The Lancet, IF: 109).

Disclaimer:Webull uses external vendor Google Translation Service for news translations where we endeavour to ensure these are correct, however, we recommend that you please double-check this information accordingly. Webull is not responsible for translation errors or issues.